<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2320">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04495101</url>
  </required_header>
  <id_info>
    <org_study_id>GC2005</org_study_id>
    <secondary_id>2020-001953-36</secondary_id>
    <nct_id>NCT04495101</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19</brief_title>
  <official_title>A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Prolastin Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Grifols, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine if Prolastin plus SMT can reduce the&#xD;
      proportion of subjects dying or requiring intensive care unit (ICU) admission on or before&#xD;
      Day 15 or who are dependent on invasive mechanical ventilation on Day 15 versus SMT alone in&#xD;
      hospitalized subjects with Coronavirus disease 2019 (COVID-19).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Dying or Requiring ICU Admission</measure>
    <time_frame>Up to Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Who are Dependent on Invasive Mechanical Ventilation</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in National Early Warning Score (NEWS)</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hospital Discharge</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU Stay</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Any Oxygen Use</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Mechanical Ventilation</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Ordinal Scale</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Value Change from Baseline in Ordinal Scale</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects in Each Severity Category of the 7-Point Ordinal Scale</measure>
    <time_frame>Day 15, Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Sustained Normalization of Temperature</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects who Sustained Normalization of Temperature</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects who Develop Acute Respiratory Distress Syndrome (ARDS)</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Time to Clinical Progression</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality Through Day 29</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Prolastin 120 mg/kg + Standard Medical Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Prolastin, two intravenous infusion (IV) doses of 120 milligram per kilogram (mg/kg), based upon the subject's body weight, on Day 1 and Day 8. Subjects will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Medical Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive all standard of care interventions while hospitalized, from Day 1 to Day 29.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prolastin</intervention_name>
    <description>Intravenous infusion 120 mg/kg</description>
    <arm_group_label>Prolastin 120 mg/kg + Standard Medical Treatment</arm_group_label>
    <other_name>Alpha1-proteinase inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Medical Treatment</intervention_name>
    <description>Standard medical treatment per local policies or guidelines</description>
    <arm_group_label>Prolastin 120 mg/kg + Standard Medical Treatment</arm_group_label>
    <arm_group_label>Standard Medical Treatment</arm_group_label>
    <other_name>SMT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Hospitalized male or female subject ≥ 18 years of age at the time of Screening who is&#xD;
             being treated for COVID-19. Subjects must be screened within 48 hours (≤ 48 hours) of&#xD;
             hospital admission.&#xD;
&#xD;
          2. Has laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by&#xD;
             qualitative Polymerase Chain Reaction (PCR) (reverse transcriptase [RT]-PCR) or other&#xD;
             commercial or public health assay in any specimen during the current hospital&#xD;
             admission prior to randomization.&#xD;
&#xD;
          3. COVID-19 illness (symptoms) of any duration, including both of the following:&#xD;
&#xD;
               1. Radiographic infiltrates by imaging (chest X-Ray, computerized tomography (CT)&#xD;
                  scan, etc.) and/or clinical assessment (evidence of rales/crackles on the exam)&#xD;
                  with peripheral oxygen saturation by pulse oximetry (SpO2) &lt;94% on room air&#xD;
&#xD;
               2. Any One of the following related to COVID-19: i. Ferritin &gt; 400 nanogram per&#xD;
                  milliliter (ng/mL), ii. Lactate dehydrogenase (LDH) &gt; 300 units per liter (U/L),&#xD;
                  iii. D-Dimers &gt; reference range, or iv. C-reactive protein (CRP) &gt; 40 milligram&#xD;
                  per liter (mg/L)&#xD;
&#xD;
          4. Subjects provides informed consent prior to the initiation of any study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects requiring invasive mechanical ventilation or ICU admission or with PaO2/FIO2&#xD;
             ≤ 150 mm Hg (ie, arterial oxygen in mm Hg divided by fraction inspired oxygen&#xD;
             concentration [eg, 0.21 for room air]).&#xD;
&#xD;
          2. Clinical evidence of any significant acute or chronic disease that, in the opinion of&#xD;
             the investigator, may place the subject at undue medical risk.&#xD;
&#xD;
          3. The subjects have had a known serious anaphylactic reaction to blood, any&#xD;
             blood-derived or plasma product, or known selective immunoglobulin A (IgA) deficiency&#xD;
             with anti-IgA antibodies.&#xD;
&#xD;
          4. A medical condition in which the infusion of additional fluid is contraindicated.&#xD;
&#xD;
          5. Shock that is unresponsive to fluid challenge and/or multiple vasopressors and&#xD;
             accompanied by multiorgan failure considered not able to be reversed by the Principal&#xD;
             Investigator.&#xD;
&#xD;
          6. Known alpha-1 antitrypsin deficiency for which the subject is already receiving&#xD;
             alpha1-proteinase inhibitor augmentation therapy.&#xD;
&#xD;
          7. Women who are pregnant or breastfeeding. Female subjects of child-bearing potential&#xD;
             must have a negative test for pregnancy blood or urine human chorionic gonadotropin&#xD;
             (HCG)-based assay at Screening/Baseline Visit.&#xD;
&#xD;
          8. Subjects for whom there is limitation of therapeutic effort such as &quot;Do not&#xD;
             resuscitate&quot; status.&#xD;
&#xD;
          9. Currently participating in another interventional clinical trial with investigational&#xD;
             medical product or device.&#xD;
&#xD;
         10. Subjects previously requiring long-term oxygen therapy (home oxygen therapy).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mireia Torres</last_name>
    <phone>+34 93 5710500</phone>
    <email>mireia.torres@grifols.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elsa Mondou, MD</last_name>
    <phone>919-316-2079</phone>
    <email>elsa.mondou@grifols.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Germans Trias</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Martinez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Ramon Badia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Valle de Hebrón</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Miravitlles, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myriam Calle, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Puente, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Príncipe de Asturias</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Miguel Rodríguez- Moro, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurora Solier, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 28, 2020</study_first_submitted>
  <study_first_submitted_qc>July 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2020</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronavirus disease</keyword>
  <keyword>Severe acute respiratory syndrome coronavirus 2</keyword>
  <keyword>SARS-CoV-2</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

